Homocysteine, folates, and the eye

Eye

Volumn 22, Issue 8, 2008, Pages 989-993

  Wright, A D ^a   Martin, N ^a   Dodson, P M ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALCOHOL; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE; PYRIDOXINE;

ALCOHOLISM; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; EUROPE; FLOUR; FOLIC ACID DEFICIENCY; FOOD PROCESSING; GENETIC POLYMORPHISM; GLAUCOMA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHYROIDISM; KIDNEY DYSFUNCTION; LENS SUBLUXATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MYOPIA; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; NORTH AMERICA; NUTRITIONAL REQUIREMENT; ORGAN TRANSPLANTATION; PRIMARY PREVENTION; PSORIASIS; PUBLIC HEALTH SERVICE; PYRIDOXINE DEFICIENCY; RECOMMENDED DRUG DOSE; RETINA ARTERY OCCLUSION; RETINA DEGENERATION; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; TWIN PREGNANCY;

EID: 50449111354     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703061     Document Type: Review

References (35)

1. McCully KS. Vascular pathology of homocysteinuria: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease; evidence of causality from a meta-analysis. BMJ 2002; 325: 1202-1206.
3. Maron BA, Loscalzo J. Homocysteine. Clin Lab Med 2006; 26: 591-609.
4. Martin SC, Tsakas-Ampatzia I, Bartlett WA, Jones AF. Measurement of plasma homocysteine by HPLC with coulometric detection. Clin Chem 1999; 45: 150-152.
5. Zappacosta B, Persichilli S, Minucci A, Scribano D, Antenucci M, Fasanella S et al. Analytical evaluation of a new immunononephelmetric method for homocysteine measurement. Clin Chim Acta 2007; 375: 165-168.
6. Cahill MT, Stinett SS, Fekrat S. A meta-analysis of plasma homocysteine, serum folate, serum B12 and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 1136-1150.
7. Martin SC, Rauz S, Marr JE, Martin N, Jones AF, Dodson PM. Plasma total homocysteine and retinal vascular disease. Eye 2000; 14: 590-593.
8. Fong ACO, Schatz H. Central retinal vein occlusion in young adults. J Ophthalmol 1993; 37: 393-417.
9. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: A population-based study. Am J Ophthalmol 2005; 139 181-182.
10. Hayreh SS, Zimmerman MB, Podhaisky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429-441.
11. Looker HC, Fagot CA, Gunter EW, Pfeiffer CM, Narayan KMV, Knowler WC et al. Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes. Diabetologia 2003; 46: 766-772.
12. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G. Moderate hyperhomocysteinemia and retinopathy in insulin-dependent diabetes. Lancet 1997; 349: 1102-1103.
13. Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with diabetes mellitus with and without retinopathy. Eye 2004; 18: 460-465.
14. Huang EJ, Khu WW, Chen YJ, Chen TH, Chang M, Lu MC et al. Homocysteine and other biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 2006; 366: 293-298.
15. Yuecel I, Yeucel G, Mueftueoglu F. Plasma homocysteine levels in noninsulin-dependent diabetes mellitus with retinopathy and neovascular glaucoma. Int Ophthalmol 2004; 25: 201-205.
16. Soedamah MSS, Chaturvedi N, Teerlink T, Idzior WR, Fuller JH, Stehouwer CDA. Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: A cross-sectional nested case control study. J Intern Med 2005; 258: 450-459.
17. Vessani RM, Ritch R, Liebmann JM, Jofe M. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol 2003; 136: 41-46.
18. Leibevitch I, Kurtz S, Shemesh S, Goldstein M, Sela BA, Lazar M et al. Hyperhomocysteinemia in psuedoexfoliation glaucoma. J Glaucoma 2003; 12: 36-39.
19. Wang G, Medeiros F, Barshop BA, Weinreb RN. Total plasma homocysteine and primary open-angle glaucoma. Am J Ophthalmol 2004; 137: 401-406.
20. Coral K, Raman R, Rathi S, Rajesh M, Sulochana KN, Angayarkanni N et al. Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration age-related macular degeneration. Eye 2006; 20: 203-207.
21. Axer-Siegel R, Bourla D, Ehrlich R, Dotan G, Benjamin Y, Gavendo S et al. Association of neovascular age-related macular degeneration and homocysteinemia. Am J Ophthalmol 2004; 137: 84-89.
22. Kamburoglu G, Gumus K, Kadayifcilar S, Eldem B. Plasma homocusteine, vitamin B12 and folate levels in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2006; 24: 565-569.
23. Jacques PF, Chylack LT, Hankinson SE, Khu PM, Rogers G, Friend J et al. Long-term nutrient intake and early agerelated nuclear lens opacities. Arch Ophthalmol 2001; 119: 1009-1019.
24. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. J Am Med Assoc 2002; 288: 2015-2022.
25. Wald NJ, Law M. A strategy to reduce to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
26. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629-1632.
27. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized controlled trials. J Am Med Assoc 2006; 296: 2720-2726.
28. Schernthaner GH, Plank C, Minar E, Biegimayer C, Koppensteiner R, Schernthaner G. No effect of homocysteine-lowering therapy on vascular inflammation and maemostasis in peripheral arterial occlusive disease. Eur J Clin Invest 2006; 26: 333-339.
29. Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E. Homocysteine lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Int Med 2007; 146: 761-767.
30. Kuzniarz M, Mitchell P, Cumming RG, Flood VM. Use of vitamin supplements and cataract: The blue mountain eye study. Am J Ophthalmol 2001; 132: 19-26.
31. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 2007; 369: 208-216.
32. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo G et al. Efficacy of folic acid supplementation in stroke prevention: A meta-analysis. Lancet 2007; 369: 1876-1882.
33. de Wals P, Tairou F, van Allen MI, Uh SH, Lowry RB, Sibbald B et al. Reduction in neural tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357: 135-142.
34. Eichholzer M, Tonz O, Zimmermann R. Folic acid: A public health challenge. Lancet 2006; 367: 1352-1361.
35. Wald NJ, Oakley GP, Hubner RA, Houlston RD, Muir KR. Should folic acid fortification be mandatory? BMJ 2007; 334: 1252-1253.